Clinical Trials Logo

Acute Hepatic Porphyria clinical trials

View clinical trials related to Acute Hepatic Porphyria.

Filter by:
  • None
  • Page 1

NCT ID: NCT05344599 Recruiting - Clinical trials for Postural Orthostatic Tachycardia Syndrome

Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome

Start date: January 19, 2022
Phase:
Study type: Observational

Postural Tachycardia Syndrome (POTS) is the most common autonomic disorder and is estimated to affect 3,000,000 individuals in the United States, with 80-85% of patients being women. The condition is characterized by a rapid increase in heart rate (HR) that occurs on standing, and chronic symptoms of cerebral hypoperfusion leading to lightheadedness, dizziness, and blurred vision. The acute hepatic porphyrias(AHP)are among the diseases that present with autonomic cardiovascular(tachycardia)and neurovisceral symptoms (abdominal pain) among others; they present with acute exacerbations Given that there is available treatment for AHP that change the natural progression of the disease, study focuses to investigate the occurrence of AHP in POTS and determine the clinical and neuro-hormonal characteristic of the POTS subgroup that will likely benefit from AHP screening. This study has one visit that involves, answering some questionnaires, coming to the lab for blood work, genetic testing, and some autonomic function tests. About 50 people will take part in this study.

NCT ID: NCT04923516 Not yet recruiting - Clinical trials for Acute Hepatic Porphyria

Prevalence of Acute Hepatic Porphyria

PHA
Start date: June 2021
Phase:
Study type: Observational

To determine the proportion of patients suffering from acute hepatic porphyria (AHP) from different hospital departments and referred to an internist referent for a suggestive clinical picture with a first negative etiological assessment.

NCT ID: NCT04883905 Recruiting - Clinical trials for Acute Hepatic Porphyria

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

ELEVATE
Start date: April 26, 2021
Phase:
Study type: Observational

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

NCT ID: NCT04056481 Approved for marketing - Clinical trials for Acute Hepatic Porphyria

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide expanded access of givosiran to patients with Acute Hepatic Porphyria (AHP).

NCT ID: NCT03547297 Terminated - Clinical trials for Acute Hepatic Porphyria

INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

Start date: May 29, 2018
Phase:
Study type: Observational

This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic process for patients in the future.

NCT ID: NCT03338816 Completed - Clinical trials for Acute Intermittent Porphyria

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Start date: November 16, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).

NCT ID: NCT02240784 Completed - Clinical trials for Acute Hepatic Porphyria

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Start date: August 2014
Phase:
Study type: Observational

The purpose of this study is to characterize the natural history and clinical management of Acute Hepatic Porphyria (AHP) patients with recurring attacks.